{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"524"},{"groupId":"OG001","value":"264"}],"units":"Participants"}],"description":"An Adverse Event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.","groups":[{"description":"Participants received 480 mg IV Nivolumab in an approximately 30-minute infusion on Day 1 of each 4-week treatment cycle until unacceptable toxicity, withdrawal of consent, completion of 12 months of treatment (from first dose of study treatment), disease recurrence, or the study ends, whichever occurred first. Participants began study treatment (Cycle 1) within 3 calendar days of randomization. Subsequent cycles were initiated within ± 3 days of the target visit date.","id":"OG000","title":"Nivolumab"},{"description":"Nivolumab matched placebo (0.9% Sodium Chloride for Injection/5% Dextrose for Injection) IV in a 30-minute infusion on Day 1 of each 4-week treatment cycle until unacceptable toxicity, withdrawal of consent, completion of 12 months of treatment (from first dose of study treatment), disease recurrence, or the study ends, whichever occurred first. In the event of disease recurrence, participants on the blinded nivolumab or placebo portion will be offered the option to receive open-label on-protocol nivolumab treatment. Participants received 480 mg IV Nivolumab in a 30-minute infusion on Day 1 of each 4-week treatment cycle until unacceptable toxicity, recurrence/progression, withdrawal of consent, completion of 12 months of treatment from first dose of open-label study treatment, whichever occurred first.","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose up to 30 days post last dose of the blinded phase (up to 13 months)","title":"Number of Participants Experiencing Adverse Events Leading to Discontinuation","type":"SECONDARY","unitOfMeasure":"Participants"}